Skip to content

Allphase Pharma Consulting, LLC

A Professional Service Provider for the Pharma Industry

Allphase Pharma Consulting, LLC
Menu

Primary menu

  • CONTACT
  • BLOGS
    • The Viewpoint
    • The News
    • Recent Literature
    • Did you know…?
    • QIDP Antibiotics
  • LEGAL
  • WELCOME

Secondary menu

  • The News
  • The Viewpoint
  • Did you know…?
  • Recent Literature
  • QIDP Antibiotics

Tag Archives: trial design

OLOROFIM in a TIGHT SPOT

Posted on September 22, 2025 by Harald — No Comments ↓

Regulatory and development status of Olorofim, a novel antifungal. Continue reading OLOROFIM in a TIGHT SPOT→

Share this:

  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to print (Opens in new window) Print
  • Click to email a link to a friend (Opens in new window) Email
  • Click to share on WhatsApp (Opens in new window) WhatsApp

Like this:

Like Loading...
Posted in Recent Literature, The News, The Viewpoint | Tagged Allphase Pharma Consulting, AmB, amphotericin B, antibiotic blog, antifungals, azoles, complete response letter, controlled clinical studies, CRL, drug toxicity, echinocandins, F2G Pharma, FDA, fluconazole, Harald Reinhart, hepatic toxicity, hepatotoxicity, IA, IC, invasive aspergillosis, invasive candidiasis, isavuconazole, John Rex, liposomal AMB, OASIS trial, PK, Shionogi, trial design, Voriconazole | Leave a reply

Go back

Your message has been sent

Rating(required)
Warning

Footer Menu

Footer menu

  • CONTACT
  • BLOGS
  • LEGAL
  • WELCOME
  • Email
Copyright © 2026 Allphase Pharma Consulting, LLC. All Rights Reserved.
Theme: Catch Box by Catch Themes
Scroll Up
%d